4-(4-苯基甲氧基苯基)丁酸乙酯 | 6660-38-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(4-苯基甲氧基苯基)丁酸乙酯
• 英文名称: 4-(4-Benzyloxyphenyl)-buttersaeureaethylester
• 英文别名: Ethyl 4-[4-(benzyloxy)phenyl]butanoate；ethyl 4-(4-phenylmethoxyphenyl)butanoate
• CAS: 6660-38-4
• 化学式: C₁₉H₂₂O₃
• 分子量: 298.382
• InChiKey: ALTBQAVUXNXHFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(4-羟基苯基)丁酸乙酯 、 氯化苄 在 sodium ethanolate 作用下， 生成 4-(4-苯基甲氧基苯基)丁酸乙酯
  参考文献：
  名称：

  Hypolipidemic analogs of ethyl 4-benzyloxybenzoate

  摘要：

  A series of compounds related to ethyl 4-benzyloxybenzoate was synthesized and evaluated for potential hypolipidemic activity in rats. Structure--activity relationships are discussed in terms of cholesterol-lowering activity together with effects on weight gain and liver lipids. A number of the compounds inhibited cholesterol and free fatty acid biosynthesis from [1-14C]acetate in rat liver slices in vitro. Ethyl 4-benzyloxybenzoate, ethyl-4-benzyloxybenzoic acid, ethyl 4-p-bromobenzyloxybenzoates, and 4-o-methoxybenzyloxyphenyl acetate exhibited the most favorable spectrum of activity.

  DOI：

  10.1021/jm00221a007

文献信息

• Compounds containing carbon-carbon linker as GPR120 agonists
  申请人：PIRAMAL ENTERPRISES LIMITED

  公开号：US10941133B2

  公开（公告）日：2021-03-09

  The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

  本发明涉及含有碳-碳连接体的式(I)化合物、立体异构体、同分异构体、药学上可接受的盐、药学上可接受的溶解物、原药、多晶型、N-氧化物、S-氧化物或其羧酸异构体；其制备工艺；包含所述化合物的药物组合物；以及它们在治疗由GPR120受体介导的疾病或紊乱中的用途。
• COMPOUNDS CONTAINING CARBON-CARBON LINKER AS GPR120 AGONISTS
  申请人：PIRAMAL ENTERPRISES LIMITED

  公开号：US20180030031A1

  公开（公告）日：2018-02-01

  The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.
• Hypolipidemic analogs of ethyl 4-benzyloxybenzoate
  作者：Keith H. Baggaley、Robin Fears、Richard M. Hindley、Brian Morgan、Elspeth Murrell、David E. Thorne

  DOI：10.1021/jm00221a007

  日期：1977.11

  A series of compounds related to ethyl 4-benzyloxybenzoate was synthesized and evaluated for potential hypolipidemic activity in rats. Structure--activity relationships are discussed in terms of cholesterol-lowering activity together with effects on weight gain and liver lipids. A number of the compounds inhibited cholesterol and free fatty acid biosynthesis from [1-14C]acetate in rat liver slices in vitro. Ethyl 4-benzyloxybenzoate, ethyl-4-benzyloxybenzoic acid, ethyl 4-p-bromobenzyloxybenzoates, and 4-o-methoxybenzyloxyphenyl acetate exhibited the most favorable spectrum of activity.